benzyne a | 50559-04-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: benzyne a
• 英文别名: 1,4-Dimethoxy-1,3-cyclohexadien-5-yne；1,4-dimethoxycyclohexa-1,3-dien-5-yne
• CAS: 50559-04-1
• 化学式: C₈H₈O₂
• 分子量: 136.15
• InChiKey: NOBXLEQKDMWJGM-UHFFFAOYSA-N

物化性质

• 沸点：
  247.4±40.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  benzyne a 在 bis(1,5-cyclooctadiene)diiridium(I) dichloride 、 四甲基乙二胺 、 silver trifluoromethanesulfonate 、 四丁基碘化铵 、 (±)-2,2 '-二(二-对甲苯基膦)-1,1 '-联萘 作用下， 反应 5.0h， 生成 (1S,2S)-2-(4-chloro-3-methylphenoxy)-5,8-dimethoxy-1,2-dihydronaphthalen-1-ol
  参考文献：
  名称：

  铱催化含苯酚的氧杂苯并降冰片二烯的不对称开环

  摘要：

  报道了一种新颖的铱催化的草酰苯并降冰片二烯与多种酚的不对称开环（ARO）反应，可高产率提供相应的反式-2-苯氧基-1,2-二氢萘-1-醇产物，中等至极好在温和条件下的对映选择性（高达98％ee）。反式产物通过一个桥头碳-氧键的对映选择性裂解而形成的1其后是S Ñ由酚类2亲核攻击。还研究了各种双膦配体，Ag（I）盐，卤化铵，碱和溶剂对反应收率和对映选择性的影响。产品2a的反式配置通过X射线晶体结构分析确认。提出了本催化反应的可能机理。

  DOI：

  10.1021/jo3018507
• 作为产物：
  描述：

  1-溴-2,5-二甲氧基苯 、 lithium diisopropyl amide 生成 benzyne a
  参考文献：
  名称：

  SAMMES P. G.; DODSWORTH D. J., J. CHEM. SOC. CHEM. COMMUN., 1979, NO 1, 33-34

  摘要：

  DOI：

文献信息

• PHOSPHORUS-CONTAINING CATALYSTS
  申请人：AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

  公开号：US20160207034A1

  公开（公告）日：2016-07-21

  The invention provides compounds of general structure I: (Ar 1 —Ar 2 —Ar 3 -E-P(=D)R 2 -) n M m X n L n ″. In this structure: •Ar 1 , Ar 2 and Ar 3 are aromatic groups wherein: —Ar 1 and Ar 3 are in a 1,3 relationship on Ar 2 , —each of Ar 1 , Ar 2 and Ar 3 optionally comprises one or more ring substituents of formula YR′ r wherein each Y independently is absent or is O, S, B, N or Si and each R′ is independently H, halogen, alkyl, cycloalkyl, aryl or heteroaryl and r is 1, 2 or 3, where r is 1 if Y is absent or is O or S, 2 if Y is B or N and 3 if Y is Si, —Ar 1 , Ar 2 and Ar 3 are each independently carbocyclic or heterocyclic and each is independently monocyclic, bicyclic or polycyclic and each ring of each of Ar 1 , Ar 2 and Ar 3 independently has 5, 6 or 7 ring atoms; •E is absent or is selected from the group consisting of O, S, NR″, SiR″ 2 , AsR″ 2 and CR″ 2 ; •M is a complexing metal; •X is selected from the group consisting of H, F, Br, CI, I, OTf, dba (dibenzylidene acetone), OC(═O)CF 3 and OAc; •L is selected from the group consisting of PR″ 2 , NR″ 2 , OR″, SR″, SiR″ 3 , AsR″ 3 , alkene, alkyne, aryl and heteroaryl, each of said alkene, alkyne, aryl and heteroaryl being optionally substituted, for example with one or more halogens and/or with one or more R groups as defined herein; •each R is independently alkyl, cycloalkyl, heterocyclyl, heterocycloalkyl, aryl or -, heteroaryl; •D is absent or is ═S or —O or —Z-linker-Z—, where each Z independently is O or NH or N-alkyl and linker is an alkyl chain of 2-5 carbon atoms in length; •each R″ is independently H, alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, each other than H being optionally substituted, or R″ 2 is —Z-linker-Z— as defined above; and •m is 0 or 1 or 2; wherein if m is 0, n is 1, n′ and n″ are 0 and -- is absent; and if m is 1 or 2, n is 1 or 2 and n′ and n″ are integers such that the coordination sphere of M is filled, and D is absent.

  该发明提供了一般结构I的化合物：（Ar1—Ar2—Ar3-E-P（=D）R2-）nMmXnLn″。在这个结构中： •Ar1，Ar2和Ar3是芳香族基团，其中：—Ar1和Ar3在Ar2上呈1,3关系，—Ar1，Ar2和Ar3中的每一个可选地包括一个或多个环取代基，其化学式为YR′r，其中每个Y独立地不存在或为O、S、B、N或Si，每个R′独立地为H、卤素、烷基、环烷基、芳基或杂芳基，r为1、2或3，其中如果Y不存在或为O或S，则r为1，如果Y为B或N，则r为2，如果Y为Si，则r为3，—Ar1，Ar2和Ar3分别独立地为碳环或杂环，每个分别独立地为单环、双环或多环，每个Ar1，Ar2和Ar3的每个环独立地具有5、6或7个环原子； •E不存在或从O、S、NR″、SiR″2、AsR″2和CR″2组成的群体中选择； •M是络合金属； •X从H、F、Br、Cl、I、OTf、dba（双苯亚乙酮）、OC（═O）CF3和OAc组成的群体中选择； •L从PR″2、NR″2、OR″、SR″、SiR″3、AsR″3、烯烃、炔烃、芳基和杂芳基组成的群体中选择，所述的每个烯烃、炔烃、芳基和杂芳基可选地被取代，例如用一个或多个卤素和/或如本文所定义的一个或多个R基取代； •每个R独立地为烷基、环烷基、杂环烷基、杂环烷基、芳基或-、杂芳基； •D不存在或为═S或—O或—Z-连接-Z—，其中每个Z独立地为O或NH或N-烷基，连接体为长度为2-5个碳原子的烷基链； •每个R″独立地为H、烷基、环烷基、杂环烷基、芳基或杂芳基，除H外的每个均可选地被取代，或R″2为—Z-连接-Z—如上所定义；和 •m为0或1或2；其中如果m为0，n为1，n′和n″为0且--不存在；如果m为1或2，n为1或2，n′和n″为整数，使得M的配位球填满，并且D不存在。
• [EN] BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS CYCLIQUES PONTÉS EN TANT QU'INHIBITEURS DU VIRUS DE L'HÉPATITE C (HCV) ET LEURS APPLICATIONS PHARMACEUTIQUES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2014019344A1

  公开（公告）日：2014-02-06

  Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

  提供了一种具有公式(I)的化合物，或其立体异构体、几何异构体、互变异构体、N-氧化物、水合物、溶剂化物、代谢物、药用盐或前药，可用于治疗HCV感染或HCV疾病。还提供了包含本公开化合物之一的药物组合物，可用于治疗HCV感染或HCV疾病。
• Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof
  申请人：SUNSHINE LAKE PHARMA CO., LTD

  公开号：US20150079028A1

  公开（公告）日：2015-03-19

  Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

  提供了一种具有公式(I)的化合物，或其立体异构体、几何异构体、互变异构体、N-氧化物、水合物、溶剂化物、代谢物、药用盐或前药，可用于治疗HCV感染或HCV疾病。还提供了包含本处所述化合物的药物组合物，可用于治疗HCV感染或HCV疾病。
• Heterolysis of N-chloro-1,2,3,4-tetrahydro-1,4-iminonaphthalenes and related systems; effects of structure and of solvent on reaction pathways
  作者：John W. Davies、John R. Malpass、Richard E. Moss

  DOI：10.1016/s0040-4039(00)84913-8

  日期：1986.1

  4-tetrahydro-1,4-iminonaphthalenes substantially modifies the Ag(I)-catalysed solvolytic behaviour of this system giving tetrahydrobenzazepine derivatives; small amounts of methanol in non-polar solvents have a profound effect favouring heterolytic, rather than homolytic, NCl cleavage. Methanoquinolines are produced secondary rearrangement. Bridgehead methyl substituents also divert the reactions of

  在1,2,3,4-四氢-1,4-亚氨基萘的1,4-位上被甲基取代的氢基本上改变了该系统的Ag（I）催化的溶剂分解行为，从而得到了四氢苯并ze庚因衍生物。在非极性溶剂中少量的甲醇具有促进杂化而不是均化的NCl裂解的深刻作用。甲基喹啉产生二次重排。桥头甲基取代基还会转移N-氯-1,4-二氢-1,4-亚氨基萘的反应，从而生成喹啉衍生物。
• Preparation and spectroscopic studies of the 1,4-dihydro- 1,4-iminonaphthalene (7-azabenzonorbornadiene) ring system
  作者：John W. Davies、Michael L. Durrant、Matthew P. Walker、Djaballah Belkacemi、John R. Malpass

  DOI：10.1016/s0040-4020(01)88190-4

  日期：——

  (7-azabenzonorbornadienes) and reduced derivatives is described together with 1,4-dihydro-1,4- and 9,10-dihydro-9,10- iminoanthracenes. VT NMR studies lead to unambiguous assignment of invertomer preferences; changes in the invertomer ratios and nitrogen inversion barriers are investigated as the electronic and steric environment is modified by variation of substituents in the carbon skeleton and at nitrogen

  描述了一系列N-烷基1,4-二氢-1,4-亚氨基萘（7-氮杂苯并降冰片二烯）和还原衍生物与1,4-二氢-1,4-和9,10-二氢-9的合成，10-亚氨基蒽。VT NMR研究可明确确定内向异构体的偏好。随着碳骨架中和氮原子上取代基的变化而改变了电子和空间环境，研究了转化体比率和氮转化障碍的变化。